HRP20120634T1 - Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba - Google Patents

Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba Download PDF

Info

Publication number
HRP20120634T1
HRP20120634T1 HRP20120634TT HRP20120634T HRP20120634T1 HR P20120634 T1 HRP20120634 T1 HR P20120634T1 HR P20120634T T HRP20120634T T HR P20120634TT HR P20120634 T HRP20120634 T HR P20120634T HR P20120634 T1 HRP20120634 T1 HR P20120634T1
Authority
HR
Croatia
Prior art keywords
compound according
group
pharmaceutically acceptable
antibiotic
acceptable salts
Prior art date
Application number
HRP20120634TT
Other languages
English (en)
Inventor
Lazzarini Ameriga
Gastaldo Luciano
Candiani Gianpaolo
Ciciliato Ismaela
Losi Daniele
Marinelli Flavia
Selva Enrico
Parenti Franco
Original Assignee
Sentinella Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentinella Pharmaceuticals filed Critical Sentinella Pharmaceuticals
Publication of HRP20120634T1 publication Critical patent/HRP20120634T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Spoj formule (SEQ ID br. 2) naznačen time, da se X odabire iz skupine koja se sastoji od H, F, Cl, Br i I; u čemu su Y1, Y2,Y3,Y4 i Y5 nezavisno odabrani iz skupine koja se sastoji od, S, S O-, S=O, O- S=O i O=S=O; i u čemu se R1, R2, R3, R4, R5, R6, R7 i R8, nezavisno odabiru iz skupine koja se sastoji od H, OH, alkila i arila, uz uvjet da je barem jedan od Y1, Y2,Y3,Y4 i Y5 različit od S. Patent sadrži još 17 patentnih zahtjeva.

Claims (18)

1. Spoj formule [image] (SEQ ID br. 2) naznačen time, da se X odabire iz skupine koja se sastoji od H, F, Cl, Br i I; u čemu su Y1, Y2,Y3,Y4 i Y5 nezavisno odabrani iz skupine koja se sastoji od, S, SO-, S=O, O-S=O i O=S=O; i u čemu se R1, R2, R3, R4, R5, R6, R7 i R8, nezavisno odabiru iz skupine koja se sastoji od H, OH, alkila i arila, uz uvjet da je barem jedan od Y1, Y2,Y3,Y4 i Y5 različit od S.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da R4, R5, R6, R7 i R8 jesu H.
3. Spoj prema patentnom zahtjevu 2, naznačen time, da R1 jest H, R2 jest H i R3jest H.
4. Spoj prema patentnom zahtjevu 2, naznačen time, da R1 jest H, R2 jest H i R3jest OH.
5. Spoj prema patentnom zahtjevu 2, naznačen time, da R1 jest H, R2 jest OH i R3jest OH.
6. Spoj prema patentnom zahtjevu 2, naznačen time, da R1 jest OH, R2 jest OH i R3jest OH.
7. Spoj prema patentnom zahtjevu 2, naznačen time, da R1 jest OH, R2 jest H i R3jest H.
8. Spoj prema patentnom zahtjevu 2, naznačen time, da R1 jest OH, R2 jest H i R3jest OH.
9. Spoj prema patentnom zahtjevu 1, naznačen time, da se Y1 odabire iz skupine koja se sastoji od S-O-, S=O, O-S=O i O=S=O, a Y2,Y3,Y4 i Y5 jesu S.
10. Spoj prema patentnom zahtjevu 1, naznačen time, da se Y2 odabire iz skupine koja se sastoji od S-O-, S=O, O-S=O i O=S=O, a Y1,Y3,Y4 i Y5 jesu S.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da se Y3 odabire iz skupine koja se sastoji od S-O-, S=O, O-S=O i O=S=O, a Y1,Y2,Y4 i Y5 jesu S.
12. Spoj prema patentnom zahtjevu 1, naznačen time, da se Y4 odabire iz skupine koja se sastoji od S-O-, S=O, O-S=O i O=S=O, a Y1,Y2,Y3 i Y5 jesu S.
13. Spoj prema patentnom zahtjevu 1, naznačen time, da se Y5 odabire iz skupine koja se sastoji od S-O-, S=O, O-S=O i O=S=O, a Y1,Y2,Y3 i Y4 jesu S.
14. Farmaceutski sastav, naznačen time, da sadrži antibiotik odabran iz spojeva prema patentnom zahtjevu 1 ili njihovu farmaceutski prihvatljivu sol s kiselinom.
15. Farmaceutski sastav prema patentnom zahtjevu 14, naznačen time, da nadalje sadrži farmaceutski prihvatljiv nosilac.
16. Spojevi prema patentnom zahtjevu 1 ili njihove farmaceutski prihvatljive soli s kiselinom, naznačeni time, da su za uporabu kao lijek.
17. Uporaba spojeva prema patentnom zahtjevu 1 ili njihovih farmaceutski prihvatljivih soli s kiselinom, naznačena time, da jest za proizvodnju lijeka za liječenje ili prevenciju bakterijskih infekcija.
18. Uporaba spojeva prema patentnom zahtjevu 1 i njihovih netoksičnih soli s kiselinom, naznačena time, da jest za pospješivanje rasta životinja
HRP20120634TT 2005-01-26 2012-08-02 Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba HRP20120634T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/045,628 US7351687B2 (en) 2003-07-18 2005-01-26 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
PCT/US2005/002733 WO2006080920A1 (en) 2005-01-26 2005-01-27 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
HRP20120634T1 true HRP20120634T1 (hr) 2012-08-31

Family

ID=36740829

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120634TT HRP20120634T1 (hr) 2005-01-26 2012-08-02 Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba

Country Status (26)

Country Link
US (1) US7351687B2 (hr)
EP (2) EP1848731B1 (hr)
JP (1) JP4191238B2 (hr)
KR (1) KR100896826B1 (hr)
CN (1) CN101189252B (hr)
AU (1) AU2005326149C1 (hr)
BR (1) BRPI0519942A2 (hr)
CA (1) CA2593801A1 (hr)
CY (1) CY1113030T1 (hr)
DK (1) DK1848731T3 (hr)
EA (1) EA016608B1 (hr)
ES (1) ES2387557T3 (hr)
HR (1) HRP20120634T1 (hr)
IL (1) IL184377A0 (hr)
MA (1) MA29237B1 (hr)
MX (1) MX2007009059A (hr)
NO (1) NO20073490L (hr)
NZ (1) NZ556368A (hr)
PL (1) PL1848731T3 (hr)
PT (1) PT1848731E (hr)
RS (1) RS52427B (hr)
SI (1) SI1848731T1 (hr)
TN (1) TNSN07286A1 (hr)
UA (1) UA87548C2 (hr)
WO (1) WO2006080920A1 (hr)
ZA (1) ZA200705495B (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59198982A (ja) 1983-04-28 1984-11-10 Meiji Seika Kaisha Ltd 新抗生物質sf−2240物質およびその製造法
EP0592835A3 (en) 1992-09-23 1995-03-15 Bristol Myers Squibb Co Antibiotics of type BU-4803T.
US6551591B1 (en) 2001-09-07 2003-04-22 Essential Therapeutics, Inc. Antibiotics from microbispora
US6551581B1 (en) 2001-12-27 2003-04-22 Avon Products, Inc. Methods for improving the aesthetic appearance of skin and hair
JP4163737B2 (ja) 2003-07-18 2008-10-08 ヴァイキュロン ファーマシューティカルズ, インコーポレイテッド 抗生物質107891、そのa1因子とa2因子、その薬剤学的に許容される塩、組成物、およびその使用
AU2005324536B2 (en) * 2005-01-12 2009-03-05 Sentinella Pharmaceuticals, Inc. Antibiotic 107891, its Factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
PT1855705E (pt) * 2005-01-12 2012-10-16 Sentinella Pharmaceuticals Inc Sentinella Antibiótico 107891, seus factores, seus sais aceitáveis sob o ponto de vista farmacêutico e suas composições, e sua utilização
WO2006075988A1 (en) 2005-01-12 2006-07-20 Vicuron Pharmaceuticals Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof

Also Published As

Publication number Publication date
WO2006080920A1 (en) 2006-08-03
UA87548C2 (ru) 2009-07-27
JP2008528581A (ja) 2008-07-31
ES2387557T3 (es) 2012-09-26
SI1848731T1 (sl) 2012-09-28
US20050233952A1 (en) 2005-10-20
CA2593801A1 (en) 2006-08-03
AU2005326149A1 (en) 2006-08-03
AU2005326149B2 (en) 2009-10-29
NO20073490L (no) 2007-08-07
EA016608B1 (ru) 2012-06-29
DK1848731T3 (da) 2012-09-03
MX2007009059A (es) 2008-02-12
EP1848731A4 (en) 2008-11-12
CN101189252B (zh) 2012-07-18
KR100896826B1 (ko) 2009-05-12
NZ556368A (en) 2010-09-30
EP1848731A1 (en) 2007-10-31
BRPI0519942A2 (pt) 2009-04-07
ZA200705495B (en) 2008-12-31
TNSN07286A1 (fr) 2008-12-31
MA29237B1 (fr) 2008-02-01
JP4191238B2 (ja) 2008-12-03
US7351687B2 (en) 2008-04-01
PT1848731E (pt) 2012-08-20
IL184377A0 (en) 2007-10-31
CN101189252A (zh) 2008-05-28
EP1848731B1 (en) 2012-05-23
EA200701384A1 (ru) 2008-02-28
KR20070090043A (ko) 2007-09-04
PL1848731T3 (pl) 2012-10-31
EP2402366A1 (en) 2012-01-04
RS52427B (en) 2013-02-28
CY1113030T1 (el) 2016-04-13
AU2005326149C1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
HRP20120634T1 (hr) Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba
WO2010032147A3 (en) Hydroxamic acid derivatives useful as antibacterial agents
CY1109970T1 (el) Παραγωγα 6-11 δικυκλικου κετολιδιου
EA200970535A1 (ru) Антибактериальные производные хинолина
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
TW200634021A (en) 3,6-bicyclolides
EA200970534A1 (ru) Антибактериальные производные хинолина
HK1137431A1 (en) Antibacterial quinoline derivatives
WO2006065721A3 (en) 11, 12-lactone bicyclolides
DK1340757T3 (da) 1-methylcarbapenemderivater
WO2006065743A3 (en) Tetracylic bicyclolides
HRP20120809T1 (hr) Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi , te njihova uporaba
NO20092536L (no) Antibakterielle kinolin-derivater
NO20092540L (no) Antibakterielle kinolin-derivater
NO20092541L (no) Antibakterielle kinolin-derivater
EA200970496A1 (ru) Соединения 2-алкилиндазола для лечения некоторых расстройств цнс
WO2009077485A3 (en) 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2005072204A3 (en) 6,11-3c-bicyclic 8a-azalide derivatives
TW200716143A (en) 6-11 bridged oxime erythromycin derivatives
TH147032A (th) สารต้านเชื้อแบคทีเรียชนิดใหม่สำหรับรักษาการติดเชื้อแบคทีเรียแกรมบวก
TH80554A (th) อนุพันธ์ฟลูออโรอัลคิลไพร์โรลิดีน
WO2007115278A3 (en) 3,6,11-tricyclolide
TH51768A (th) สารประกอบคาร์บาฟีเนม การใช้ของสารดังกล่าว และสารประกอบตัวกลางสำหรับสารดังกล่าว